Financial Data and Key Metrics Changes - For fiscal year 2024, the company reported revenue of $656 million, down 2% year-over-year on an organic basis, while adjusted EBITDA margin improved by approximately 300 basis points [15][48][53] - Fourth quarter revenue was $170 million, down 1% year-over-year on a reported basis and down 2% on an organic basis, with non-GAAP gross margin at 45%, up 220 basis points year-over-year [51][54] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue for the fourth quarter was $85 million, up 4% year-over-year reported and up 3% organic, with notable growth in Cryogenic Stores (67% growth) and Consumables & Instruments (14% growth) [55][56] - Multiomics revenue reached $66 million in the fourth quarter, representing 8% growth on both a reported and organic basis, driven by a 25% increase in Next Generation Sequencing [57][58] Market Data and Key Metrics Changes - The Multiomics business in China delivered organic revenue growth of 6%, outperforming a challenging market [59] - B Medical revenue was $19 million in the fourth quarter, down 35% year-over-year, reflecting a decline in orders [60] Company Strategy and Development Direction - The company announced the decision to sell B Medical to refocus on core businesses with high growth potential and margin expansion opportunities [17][46] - Key areas of focus for 2025 include portfolio optimization, operational excellence, and value-enhancing capital allocation, with a commitment to simplifying operations and aligning incentives with performance metrics [25][30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver long-term sustainable value, citing positive indicators and a backlog secured to date [37][38] - The guidance for 2025 is for organic revenue growth in the range of 3% to 5%, with expectations for Multiomics to grow low-single-digits and SMS to grow mid-single-digits [65][66] Other Important Information - The company completed a $1.5 billion share repurchase program, buying back approximately 30 million shares over the last two years [54] - The company ended the quarter with $522 million in cash and no outstanding debt, indicating a strong balance sheet [61] Q&A Session Summary Question: Guidance on fiscal '26 targets and growth assumptions - Management indicated that the guidance of 3% to 5% organic growth assumes the current market environment and reflects a prudent approach given uncertainties [70][71] Question: Dynamics behind EBITDA margin guidance - The guidance for fiscal '25 implies a stable EBITDA margin, with expectations for continued margin expansion driven by operational improvements [72][73] Question: Performance of Next Generation Sequencing (NGS) and Gene Synthesis - NGS grew 25% year-over-year, with management optimistic about continued strong performance, while Gene Synthesis saw low-single-digit growth in the quarter [76][77] Question: Impact of China tariffs and growth in China - China experienced 10% growth in the fourth quarter and 12% for the full year, with management not expecting significant tariff impacts based on current operations [78][79] Question: Outlook for the freezer market - Management expressed confidence in the freezer business, highlighting strong backlog visibility and competitive advantages in automation [85][86] Question: Pricing dynamics in the guidance for 2025 - Management acknowledged potential pricing headwinds in NGS but noted recent price stabilization as a positive indicator [97][98] Question: Timeline for the B Medical transaction - The company anticipates closing the B Medical transaction within the first half of the year [100]

Company Performance - Azenta reported quarterly earnings of $0.18 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and up from $0.13 per share a year ago, representing an earnings surprise of 63.64% [1] - Brooks, part of the Zacks Medical Info Systems industry, posted revenues of $170.06 million for the quarter ended September 2024, slightly missing the Zacks Consensus Estimate by 0.26%, and down from $172.36 million year-over-year [2] - Brooks has surpassed consensus EPS estimates four times over the last four quarters [2] Stock Performance - Brooks shares have declined approximately 29.6% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] - The current Zacks Rank for Brooks is 4 (Sell), indicating expected underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for Brooks is $0.09 on revenues of $173.56 million for the upcoming quarter, and $0.42 on revenues of $703.29 million for the current fiscal year [7] - The trend for earnings estimate revisions for Brooks is currently unfavorable, which may impact future stock performance [6] Industry Context - The Medical Info Systems industry is ranked in the top 19% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Revenue Performance - FY'24 revenue was $656 million, down 1% year over year, with organic revenue declining 2%[7] - Q4'24 revenue was $170 million, a decrease of 1% year over year, with organic revenue down 2%[4] - Sample Management Solutions revenue for FY'24 was $319 million, up 5% year over year, with organic growth of 4%[7] - Multiomics revenue for FY'24 was $255 million, up 3% year over year, with organic growth also at 3%[7] - B Medical Systems revenue for FY'24 was $83 million, down 27% year over year, with organic revenue also down 27%[7] - Revenue for the total year ended September 30, 2024, was $656 million, a slight decrease of 1% compared to $665 million in 2023[41] Profitability Metrics - Adjusted EBITDA for FY'24 was $49 million, with an Adjusted EBITDA margin of 7.5%, an improvement of about 300 basis points year over year[10] - FY'25 organic revenue growth is expected to be between 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points[1] - Non-GAAP diluted EPS for FY'24 was $0.41, compared to $0.31 in FY'23, reflecting a 32% increase[10] - Gross profit for the three months ended September 30, 2024, was $69,413,000, compared to $68,034,000 for the same period in 2023, reflecting a slight increase[27] - GAAP gross profit for the quarter ended September 30, 2024, was $69,413,000, representing a gross margin of 40.8%, up from 39.5% in the same quarter of 2023[35] - Non-GAAP adjusted gross profit for the quarter ended September 30, 2024, was $76,455,000, with a margin of 45.0%, compared to $73,730,000 and 42.8% in the same quarter of 2023[35] Losses and Charges - Operating loss for the three months ended September 30, 2024, was $(12,292,000), an improvement from $(16,628,000) in the same period last year[27] - Net loss for the three months ended September 30, 2024, was $(4,984,000), compared to a net income of $3,375,000 for the same period in 2023[27] - The company reported a basic net loss per share of $(0.10) for the three months ended September 30, 2024, compared to a profit of $0.05 in the same period last year[27] - Restructuring charges amounted to $11,808 thousand for the year ended September 30, 2024, compared to $4,577 thousand in 2023[32] - The company reported a significant impairment of goodwill and intangible assets amounting to $115,975 thousand for the year ended September 30, 2024[40] Cash and Assets - Cash and cash equivalents decreased to $310,929,000 as of September 30, 2024, down from $678,910,000 a year earlier[28] - Total assets decreased to $2,100,041,000 from $2,885,720,000 year-over-year[29] - Total stockholders' equity decreased to $1,768,967,000 from $2,534,500,000 compared to the previous year[29] Management Changes - Lawrence Y. Lin has been appointed as Chief Financial Officer, succeeding Herman Cueto[18] Strategic Initiatives - The company is pursuing a sale of B Medical Systems to simplify its portfolio and enhance revenue growth and profitability[16] - The company expects continued focus on transformation and productivity improvements to enhance long-term operational efficiency[37] - Transformation costs for the quarter ended September 30, 2024, were $3,971 thousand, reflecting ongoing strategic projects aimed at long-term benefits[40] Other Financial Metrics - Non-GAAP adjusted net income from continuing operations was $21,804 thousand for the year ended September 30, 2024, up from $20,599 thousand in 2023[32] - Non-GAAP adjusted net income excluding stock-based compensation was $34,246 thousand for the year ended September 30, 2024, compared to $28,671 thousand in 2023[32] - Earnings before interest, taxes, depreciation, and amortization (EBITDA) for continuing operations was $9,109 thousand for the quarter ended September 30, 2024[33] - Non-GAAP adjusted operating income for September 30, 2024, was $9,860 thousand, compared to $3,404 thousand in the previous year[38]

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 ...

BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes.The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.aze ...

BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. ...

Company Leadership Transition - Azenta, Inc. announced the appointment of John P. Marotta as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring after 14 years [1][3] - Dr. Schwartz will remain as an advisor to ensure a smooth transition [1] Executive Background - Mr. Marotta has over 20 years of experience in leading global companies in life sciences, medical devices, and diagnostics, previously serving as CEO and President of PHC Holdings Corporation [2] - He has held senior executive roles at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health, demonstrating a track record of organic revenue growth and operational efficiencies [2] Board's Confidence - Frank E. Casal, Chairman of the Azenta Board, expressed confidence in Mr. Marotta's ability to lead the company into its next chapter, highlighting his extensive experience in high-growth life sciences businesses [3] - Mr. Marotta expressed excitement about joining Azenta and emphasized the company's strong foundation and growth opportunities [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services for drug development, clinical research, and advanced cell therapies [4] - The company operates globally with a presence in North America, Europe, and Asia, supporting top pharmaceutical, biotech, academic, and healthcare institutions [4]

BURLINGTON, Mass., Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20. GENEWIZ Week will showcase our commitment to providing cutting-edge solutions to researchers worldwide through a series of workshops, an awards program, and engaging prizes and promotions.Registration for GENEWIZ Week 2024 is now open.The ...

Azenta, Inc. (NASDAQ:AZTA) Q3 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Sophia Knopp - Evercore ISI Noah Lewis - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings, and welcome to the Azenta Third Quarter 2024 Financial Results. ...

Azenta (AZTA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 128.57%. A quarter ago, it was expected that this supplier to semiconductor manufacturers would post earnings of $0.02 per share when it actually produced earnings of $0.05, delivering a surprise of 150%.Over the last four ...